Leukemia

The Bruton tyrosine kinase inhibitor showed a statistically-significant and clinically-meaningful improvement in progression-free survival in patients with previously-treated CLL.

An extraordinary group of nurses, led by nurse manager Taylor Andrews, B.S., RN, BMTCN, have made it their mission to become fairy godmothers for the patients they care for in the bone marrow transplant unit and to make their wishes come true.

When you are first told that you’re sick, very sick, it’s like a kick in the head. It leaves you stunned and not quite sure which way to turn. If you’re as lucky as I was, you have Sandy Allen-Bard, NP, to turn to.

Most people have heard the term "new normal" for individuals living, surviving and struggling with cancer. What actually does that mean?

The FDA has approved a supplemental new drug application for Tibsovo as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia who are 75 years and older or are ineligible to receive intensive chemotherapy.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

Risk for disease progression among patients with chronic lymphocytic leukemia over time differed between those with mutated or unmutated disease, showing that gene somatic hypermutation plays a role throughout the disease course.

Extraordinary Healer® Award finalist Angela Hammack, B.S.N., RN, OCN, discussed how she began running marathons to raise awareness – and $100,000 – for cancer.

In this week’s episode, we spoke with a young adult and a child life specialist who discussed the importance of focusing on the needs of AYAs with cancer.

An expert discusses new treatment options for patients diagnosed with CLL.

Patients with relapsed or refractory chronic lymphocytic leukemia may have more options now than ever before, according to William G. Wierda, M.D., Ph.D.

While novel agents continue to evolve in the treatment landscape for chronic lymphocytic leukemia, many may start to be combined in the front-line setting as well, according to Matthew S. Davids, M.D., MMSc.

Here are the top 5 CURE stories for March 2019.

Helping others is the last phase of recovery.

Time-limited treatment could be the new wave of research in the treatment of chronic lymphocytic leukemia (CLL), according to Nicole Lamanna, M.D.

Here are the top 5 CURE stories for February 2019.

Brian Boyle, who plays center for the New Jersey Devils, has announced that his blood cancer is in remission.

The Food and Drug Administration granted a priority review to Tibsovo (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

A CLL diagnosis comes with new challenges, from understanding signs and symptoms and what the different stages mean.

Understanding CLL as a chronic disease.

Knowing treatment options and the possibilities of supportive care.

Utilizing clinical trials and understanding potential side effects and complications.

Finding follow-up care and emotional support.

Serving as a caregiver for a loved one going through a CLL diagnosis and treatment while utilizing resources to take care of oneself.

A list of helpful resources to assist people with CLL and their families cope with the emotional and practical aspects of the disease.

Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to phase 3 findings published in the New England Journal of Medicine.

Ian W. Flinn, M.D., Ph.D., discusses the use of Copiktra, which was approved in September for patients with relapsed/refractory chronic lymphocytic leukemia.

The Food and Drug Administration approved Imbruvica plus Gazyva for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

An acute promyelocytic leukemia survivor reflects on fear, courage and the future.

Toronto’s Jeff Lipton, PhD, MD, FRCPC, shares his thoughts on the outlook for blood cancers.